Oncology Gene Therapy Market Report: 2027-2031 Forecast, Strategic Opportunities by Approach, Vector, Indication, Product, Route of Administration and Country - Strategic Analysis of 15 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Forecast Approach
2.2 Data Sources
2.3 Scope & Definitions
2.4 Limitations

3.1 Mechanism of Action & Key Components
3.2 Evolution of the Technology
3.3 Adjacent Modalities

4.1 Global Market Overview by Country
4.2 Global Market by Approach - Overview
4.3 Global Market by Vector - Overview
4.4 Global Market by Indication - Overview
4.5 Global Market by Product - Overview
4.6 Global Market by Route of Administration - Overview

5.1 Approved Product Registry
5.2 Technology Benchmarking
5.3 Commercial Benchmarking - Top-Selling Products
5.4 Regulatory Risk Case Studies

6.1 Pipeline Overview
6.2 Pipeline Distribution by Phase
6.3 Target & Indication Crowding
6.4 Sponsor Geographic Distribution

7.1 Core Platform Technologies
7.2 Next-Generation Approaches
7.3 Delivery & Formulation
7.4 Platform Technology Licensors

8.1 Combinations with Immunotherapy
8.2 Combinations with Targeted Therapy
8.3 Commercial and Biological Rationale

9.1 FDA Approval Pathways
9.2 EMA & NMPA Pathways
9.3 HTA & Reimbursement Dynamics
9.4 Patent & Biosimilar Overview

10.1 Expiry Timeline
10.2 Biosimilar & Generic Pipeline
10.3 Anticipated Price Erosion

11.1 Key Originators
11.2 Why Global Pharma Is Buying In

12.1 Recent Developments - Importance and How to Use This Section
12.2 AstraZeneca acquires EsoBiotec for in vivo cell therapy
12.3 AbbVie acquires Capstan for $2.1 billion
12.4 FDA removes REMS requirements for approved CAR-T therapies
12.5 Gilead's Kite acquires Interius for in vivo CAR-T
12.6 BMS acquires Orbital Therapeutics for $1.5 billion
12.7 Gilead to acquire Arcellx for $7.8 billion
12.8 Second FDA rejection for Replimune's RP1
12.9 Cretostimogene shows durable responses in bladder cancer
12.10 FDA grants accelerated approval to RP1 in melanoma
12.11 enGene prepares detalimogene filing in bladder cancer

13.1 Manufacturing Capacity Landscape
13.2 CDMO Competitive Positioning
13.3 In-House vs. Outsourced Manufacturing Trends
13.4 Capacity Bottlenecks and Outlook

14.1 Market Structure
14.2 Big Pharma / Large-Cap Portfolios
14.3 Emerging and China-Originated Players
14.4 Outlook

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Key Investment Risks

16.1 White-Space Opportunities
16.2 Partnering Strategy Guidance

17.1 Oncolytic viruses
17.2 Gene-modified cell therapy (CAR-T/TCR)
17.3 Gene transfer
17.4 Gene editing
17.5 Other approaches

18.1 Lentiviral vectors
18.2 Retroviral vectors
18.3 Adenoviral vectors
18.4 Herpes simplex virus vectors
18.5 AAV vectors
18.6 Non-viral delivery (LNP/electroporation)

19.1 B-cell lymphoma
19.2 Leukemia
19.3 Multiple myeloma
19.4 Melanoma
19.5 Bladder cancer
19.6 Other solid tumors
19.7 Other indications

20.1 Yescarta (axicabtagene ciloleucel)
20.2 Kymriah (tisagenlecleucel)
20.3 Breyanzi (lisocabtagene maraleucel)
20.4 Abecma (idecabtagene vicleucel)
20.5 Carvykti (ciltacabtagene autoleucel)
20.6 Tecartus (brexucabtagene autoleucel)
20.7 Imlygic (talimogene laherparepvec)
20.8 Adstiladrin (nadofaragene firadenovec)
20.9 Other products

21.1 Intravenous
21.2 Intratumoral
21.3 Intravesical
21.4 Other routes

22.1 AbbVie
22.2 Amgen
22.3 Arcellx
22.4 AstraZeneca
22.5 Autolus Therapeutics
22.6 Bristol Myers Squibb
22.7 CG Oncology
22.8 enGene
22.9 Ferring Pharmaceuticals
22.10 Gilead Sciences (Kite)
22.11 Johnson & Johnson
22.12 Legend Biotech
22.13 Novartis
22.14 Orbital Therapeutics
22.15 Replimune

23.1 Abbreviations
23.2 Report Limitations Restated

Table 1 Global Market by Country
Table 2 Global Market by Approach
Table 3 Global Market by Vector
Table 4 Global Market by Indication
Table 5 Global Market by Product
Table 6 Global Market by Route of Administration
Table 7 Oncolytic viruses by Country
Table 8 Gene-modified cell therapy (CAR-T/TCR) by Country
Table 9 Gene transfer by Country
Table 10 Gene editing by Country
Table 11 Other approaches by Country
Table 12 Lentiviral vectors by Country
Table 13 Retroviral vectors by Country
Table 14 Adenoviral vectors by Country
Table 15 Herpes simplex virus vectors by Country
Table 16 AAV vectors by Country
Table 17 Non-viral delivery (LNP/electroporation) by Country
Table 18 B-cell lymphoma by Country
Table 19 Leukemia by Country
Table 20 Multiple myeloma by Country
Table 21 Melanoma by Country
Table 22 Bladder cancer by Country
Table 23 Other solid tumors by Country
Table 24 Other indications by Country
Table 25 Yescarta (axicabtagene ciloleucel) by Country
Table 26 Kymriah (tisagenlecleucel) by Country
Table 27 Breyanzi (lisocabtagene maraleucel) by Country
Table 28 Abecma (idecabtagene vicleucel) by Country
Table 29 Carvykti (ciltacabtagene autoleucel) by Country
Table 30 Tecartus (brexucabtagene autoleucel) by Country
Table 31 Imlygic (talimogene laherparepvec) by Country
Table 32 Adstiladrin (nadofaragene firadenovec) by Country
Table 33 Other products by Country
Table 34 Intravenous by Country
Table 35 Intratumoral by Country
Table 36 Intravesical by Country
Table 37 Other routes by Country

Figure 1 Key Graphic - The CAR-T changing of the guard
Figure 1 Global Market Pareto Chart
Figure 2 Global Market by Approach - Base vs. Final
Figure 3 Global Market by Approach Base Year
Figure 4 Global Market by Approach End Year
Figure 5 Approach Share by Year
Figure 6 Approach Segments Growth
Figure 7 Global Market by Vector - Base vs. Final
Figure 8 Global Market by Vector Base Year
Figure 9 Global Market by Vector End Year
Figure 10 Vector Share by Year
Figure 11 Vector Segments Growth
Figure 12 Global Market by Indication - Base vs. Final
Figure 13 Global Market by Indication Base Year
Figure 14 Global Market by Indication End Year
Figure 15 Indication Share by Year
Figure 16 Indication Segments Growth
Figure 17 Global Market by Product - Base vs. Final
Figure 18 Global Market by Product Base Year
Figure 19 Global Market by Product End Year
Figure 20 Product Share by Year
Figure 21 Product Segments Growth
Figure 22 Global Market by Route of Administration - Base vs. Final
Figure 23 Global Market by Route of Administration Base Year
Figure 24 Global Market by Route of Administration End Year
Figure 25 Route of Administration Share by Year
Figure 26 Route of Administration Segments Growth
Figure 27 Oncolytic viruses Growth
Figure 28 Gene-modified cell therapy (CAR-T/TCR) Growth
Figure 29 Gene transfer Growth
Figure 30 Gene editing Growth
Figure 31 Other approaches Growth
Figure 32 Lentiviral vectors Growth
Figure 33 Retroviral vectors Growth
Figure 34 Adenoviral vectors Growth
Figure 35 Herpes simplex virus vectors Growth
Figure 36 AAV vectors Growth
Figure 37 Non-viral delivery (LNP/electroporation) Growth
Figure 38 B-cell lymphoma Growth
Figure 39 Leukemia Growth
Figure 40 Multiple myeloma Growth
Figure 41 Melanoma Growth
Figure 42 Bladder cancer Growth
Figure 43 Other solid tumors Growth
Figure 44 Other indications Growth
Figure 45 Yescarta (axicabtagene ciloleucel) Growth
Figure 46 Kymriah (tisagenlecleucel) Growth
Figure 47 Breyanzi (lisocabtagene maraleucel) Growth
Figure 48 Abecma (idecabtagene vicleucel) Growth
Figure 49 Carvykti (ciltacabtagene autoleucel) Growth
Figure 50 Tecartus (brexucabtagene autoleucel) Growth
Figure 51 Imlygic (talimogene laherparepvec) Growth
Figure 52 Adstiladrin (nadofaragene firadenovec) Growth
Figure 53 Other products Growth
Figure 54 Intravenous Growth
Figure 55 Intratumoral Growth
Figure 56 Intravesical Growth
Figure 57 Other routes Growth